Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241927 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
A Phase 2 study, sponsored by Nina Bhardwaj.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03241927: Clinical Trial Phase 2 study, sponsored by Nina Bhardwaj.
NCT03241927 is a Phase 2 study that was terminated before completion, run by Nina Bhardwaj. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03241927, a Phase 2 study, was terminated before completion, sponsored by Nina Bhardwaj.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma. Pembrolizumab across a range of doses in phase I investigation has demonstrated clinical efficacy with RR approximately 27%. By better understanding how NK cell function and exhaustion interplays with PD1 function and activity, potentially more efficacious combination therapies can be developed. The pharmacodynamic studies to be performed as part of this trial will provide such information.
Primary Outcome
NK cell exhaustion will be assess by flow cytometry and expressed as % of LAMP-1 positive cells.
Interventions
- BIOLOGICAL Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2018-06-06 |
| Phase | Phase 2 |
Why NCT03241927 stopped before completion
NCT03241927 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03241927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03241927 about?
NCT03241927 is a clinical study titled "Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)". Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma. Pembrolizumab across a range of doses in phase I investigation has demonstrated cli...
What is the current status of trial NCT03241927?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-12-20. Estimated completion is 2018-06-06.
What interventions are being tested in trial NCT03241927?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03241927?
This trial is sponsored by Nina Bhardwaj, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03241927's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI